Black Diamond Therapeutics Inc (BDTX)

[dcaf7]

Titles of BDTX presentations at triple meeting:
1. Oral presentation, Oct 8, 2023, "BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastases".
2. Poster, "Pre-clinical evaluation of next-generation inhibitor targeting a wide spectrum of oncogenic BRAF dimers".
3. Poster, "Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers".